A New Approach in COPD: Biologic Therapy in Patients With Type 2 Inflammation

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MKD865. CME/MOC/AAPA credit will be available until December 19, 2025.
Targeting a New Approach in COPD: Understanding the Potential Role of Biologic Therapy in Patients With Evidence of Type 2 Inflammation
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Disclosure information is available at the beginning of the video presentation.